Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Globe Newswire (Thu, 23-Jul 9:15 AM ET)
Globe Newswire (Mon, 13-Jul 7:05 AM ET)
Longeveron Appoints Marie Washburn as Chief Financial Officer
Globe Newswire (Mon, 6-Jul 4:05 PM ET)
Globe Newswire (Thu, 18-Jun 9:20 AM ET)
Globe Newswire (Tue, 9-Jun 9:20 AM ET)
Longeveron to Present at BIO International Convention 2026
Globe Newswire (Thu, 4-Jun 9:15 AM ET)
Globe Newswire (Wed, 20-May 4:05 PM ET)
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Globe Newswire (Wed, 13-May 4:05 PM ET)
Globe Newswire (Mon, 11-May 9:10 AM ET)
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Longeveron - Class A trades on the NASDAQ stock market under the symbol LGVN.
As of July 24, 2026, LGVN stock price declined to $0.60 with 156,574 million shares trading.
LGVN has a beta of -0.17, meaning it tends to be less sensitive to market movements. LGVN has a correlation of 0.00 to the broad based SPY ETF.
LGVN has a market cap of $18.96 million. This is considered a Sub-Micro Cap stock.
Last quarter Longeveron - Class A reported $398,000 in Revenue and -$.19 earnings per share. This beat revenue expectation by $64,800 and met earnings estimates .
In the last 3 years, LGVN traded as high as $35.60 and as low as $.48.
The top ETF exchange traded funds that LGVN belongs to (by Net Assets): VTI, VXF.
LGVN has underperformed the market in the last year with a price return of -65.5% while the SPY ETF gained +17.7%. LGVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.5% and -7.8%, respectively, while the SPY returned +4.6% and -1.7%, respectively.
LGVN support price is $.57 and resistance is $.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGVN shares will trade within this expected range on the day.
